行情

ELDN

ELDN

Eledon Pharmaceuticals, Inc.
NASDAQ

实时行情|Nasdaq Last Sale

7.00
0.00
0.00%
盘后: 7.00 0 0.02% 16:00 09/17 EDT
开盘
6.93
昨收
7.00
最高
7.17
最低
6.53
成交量
16.63万
成交额
--
52周最高
27.32
52周最低
5.91
市值
1.00亿
市盈率(TTM)
-0.8042
分时
5日
1月
3月
1年
5年
Eledon Pharmaceuticals 将于 9 月出席两次投资者会议
Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic ...
GlobeNewswire · 09/01 20:05
两个净流动资产价值股票值得考虑
GuruFocus News · 08/23 13:48
Eledon Pharmaceuticals Q2 每股收益 $(0.50) 超过 $(0.57) 估计
Eledon Pharmaceuticals (NASDAQ:ELDN) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.57) by 12.28 percent. This is a 233.33 percent decrease over losses of $(0.15) per
Benzinga · 08/12 20:38
Eledon Pharmaceuticals 每股收益超过 0.07 美元
Eledon Pharmaceuticals (NASDAQ:ELDN): Q2 GAAP EPS of -$0.50 beats by $0.07. The company had approximately $101.1 million in cash and cash equivalents as of June 30, 2021, compared to $114.2
Seekingalpha · 08/12 20:11
The Daily Biotech Pulse:Xeris 启动甲状腺功能亢进症研究,Merck-Eisai Snag FDA 对药物组合的批准,Jazz Pharma 的决定日
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11)
Benzinga · 08/12 12:09
预计 2021 年 8 月 12 日的收益
  Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter.
Benzinga · 08/12 08:14
生物技术的未来一周(8 月 8 日至 14 日):Jazz Pharma FDA 的决定、收益泛滥和 IPO 成为焦点
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the...
Benzinga · 08/08 14:03
Eledon Pharmaceuticals 将于 2021 年 8 月 12 日星期四发布第二季度财务业绩
Eledon Pharmaceuticals ("Eledon") (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amy...
GlobeNewswire · 08/02 12:05
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解ELDN最新的财务预测,通过ELDN每股收益,每股净资产,每股现金流等数据分析Eledon Pharmaceuticals, Inc.近期的经营情况,然后做出明智的投资选择。
分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测ELDN价格均价为30.80,最高价位39.00,最低价为22.00。
EPS
机构持股
总机构数: 48
机构持股: 1,010.91万
持股比例: 70.66%
总股本: 1,430.66万
类型机构数股数
增持
12
222.15万
建仓
7
41.69万
减持
7
9.96万
平仓
6
118.30万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
制药
-0.40%
制药与医学研究
-0.10%
高管信息
Non-Executive Chairman/Independent Director
Keith Katkin
President/Chief Scientific Officer/Director
Steven Perrin
Chief Executive Officer/Director
David-Alexandre Gros
Chief Financial Officer
Paul Little
Chief Compliance Officer/General Counsel/Secretary
Bryan Smith
Other
Jeff Bornstein
Other
David Hovland
Independent Director
Jan Hillson
Independent Director
June Lee
Independent Director
Gary Lyons
Independent Director
John McBride
Independent Director
Walter Ogier
暂无数据
ELDN 简况
Eledon Pharmaceuticals Inc是一家临床阶段的生物制药公司。该公司专注于为需要器官或细胞移植或患有肌萎缩侧索硬化症(ALS)的自身免疫性疾病患者开发药物。该公司的主要候选产品AT-1501是一种人源化单克隆抗体(mAb),旨在靶向CD40配体(CD40L)(也称为 CD154),这是一种在人类免疫系统T细胞表面表达的分子。CD40或CD40L信号在产生促炎反应中的核心作用使其成为治疗性干预自身免疫疾病、诱导和维持移植耐受性和神经炎症的候选者。阻断CD40L通路的激活可防止多种动物的急性和长期同种异体移植排斥反应,并改善自身免疫和ALS临床前模型中的疾病进展和病理。

微牛提供Eledon Pharmaceuticals Inc(NASDAQ-ELDN)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的ELDN股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易ELDN股票基本功能。